[go: up one dir, main page]

MX2018013815A - Metodos y materiales para estadificar y tratar cancer de piel. - Google Patents

Metodos y materiales para estadificar y tratar cancer de piel.

Info

Publication number
MX2018013815A
MX2018013815A MX2018013815A MX2018013815A MX2018013815A MX 2018013815 A MX2018013815 A MX 2018013815A MX 2018013815 A MX2018013815 A MX 2018013815A MX 2018013815 A MX2018013815 A MX 2018013815A MX 2018013815 A MX2018013815 A MX 2018013815A
Authority
MX
Mexico
Prior art keywords
skin cancer
materials
methods
staging
treating skin
Prior art date
Application number
MX2018013815A
Other languages
English (en)
Other versions
MX388345B (es
Inventor
Meves Alexander
Original Assignee
Mayo Found Medical Education & Res
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mayo Found Medical Education & Res filed Critical Mayo Found Medical Education & Res
Publication of MX2018013815A publication Critical patent/MX2018013815A/es
Publication of MX388345B publication Critical patent/MX388345B/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • G01N33/5751—
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B25/00—ICT specially adapted for hybridisation; ICT specially adapted for gene or protein expression
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B25/00—ICT specially adapted for hybridisation; ICT specially adapted for gene or protein expression
    • G16B25/10—Gene or protein expression profiling; Expression-ratio estimation or normalisation
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
    • G16H50/00—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics
    • G16H50/20—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for computer-aided diagnosis, e.g. based on medical expert systems
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/112—Disease subtyping, staging or classification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/118—Prognosis of disease development
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Physics & Mathematics (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Medical Informatics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Immunology (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Evolutionary Biology (AREA)
  • Spectroscopy & Molecular Physics (AREA)
  • Theoretical Computer Science (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Oncology (AREA)
  • Hospice & Palliative Care (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Primary Health Care (AREA)
  • Data Mining & Analysis (AREA)
  • Databases & Information Systems (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)

Abstract

Este documento proporciona métodos y materiales para estadificar y tratar el cáncer de piel (por ejemplo, lesiones cutáneas pigmentadas, malignas y metastásicas). Por ejemplo, se proporcionan métodos y materiales para usar un perfil de expresión de ITLP y/o modelos que incluyen un perfil de expresión de ITLP para estadificar el cáncer de piel y/o determinar opciones de tratamiento para pacientes con cáncer de piel.
MX2018013815A 2016-05-10 2017-05-10 Métodos y materiales para estadificar cáncer de piel y seleccionar tratamiento. MX388345B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662334302P 2016-05-10 2016-05-10
PCT/US2017/031908 WO2017196944A1 (en) 2016-05-10 2017-05-10 Methods and materials for staging and treating skin cancer

Publications (2)

Publication Number Publication Date
MX2018013815A true MX2018013815A (es) 2019-07-04
MX388345B MX388345B (es) 2025-03-19

Family

ID=60267789

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2018013815A MX388345B (es) 2016-05-10 2017-05-10 Métodos y materiales para estadificar cáncer de piel y seleccionar tratamiento.

Country Status (9)

Country Link
US (1) US11060151B2 (es)
EP (1) EP3455761B1 (es)
CN (1) CN109477147A (es)
AU (1) AU2017261688B2 (es)
BR (1) BR112018073014A2 (es)
EA (1) EA201892562A1 (es)
ES (1) ES2906987T3 (es)
MX (1) MX388345B (es)
WO (1) WO2017196944A1 (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20160222457A1 (en) 2012-11-14 2016-08-04 Mayo Foundation For Medical Education And Research Methods and materials for identifying malignant skin lesions
US20170275700A1 (en) 2014-08-14 2017-09-28 Mayo Foundation For Medical Education And Research Methods and materials for identifying metastatic malignant skin lesions and treating skin cancer
EP3455761B1 (en) 2016-05-10 2021-12-22 Mayo Foundation for Medical Education and Research Methods and materials for staging and treating skin cancer
CA3107401A1 (en) 2018-07-25 2020-01-30 Skylinedx B.V. Gene signatures for predicting metastasis of melanoma and patient prognosis

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040010045A1 (en) 2001-09-07 2004-01-15 Taolin Yi Therapeutic compositions comprised of pentamidine and methods of using same to treat cancer
BR0316111A (pt) 2002-11-21 2005-09-13 Wyeth Corp Métodos para diagnosticar rcc e outros tumores sólidos
US20070154889A1 (en) 2004-06-25 2007-07-05 Veridex, Llc Methods and reagents for the detection of melanoma
TW200719903A (en) 2005-04-19 2007-06-01 Combinatorx Inc Compositions for the treatment of neoplasms
NZ593224A (en) 2006-01-11 2012-10-26 Genomic Health Inc Gene expression markers (fap) for colorectal cancer prognosis
JP4943074B2 (ja) * 2006-07-03 2012-05-30 シスメックス株式会社 がん転移の判定方法及び装置
US8450057B2 (en) 2006-08-14 2013-05-28 The Brigham And Women's Hospital, Inc. Diagnostic tests using gene expression ratios
PT2062049E (pt) 2006-09-06 2014-07-28 Univ California Diagnóstico molecular e classificação de melanoma maligno
EP2191020A2 (en) 2007-08-16 2010-06-02 Genomic Health, Inc. Gene expression markers of recurrence risk in cancer patients after chemotherapy
ES2424329T3 (es) 2008-03-05 2013-10-01 The Regents Of The University Of California Diagnóstico molecular y clasificación de melanoma maligno
WO2010125462A2 (en) 2009-05-01 2010-11-04 Oncozyme Pharma Inc. Pentamidine combinations for treating cancer
US20140045915A1 (en) 2010-08-31 2014-02-13 The General Hospital Corporation Cancer-related biological materials in microvesicles
AU2011305696A1 (en) 2010-09-20 2013-05-02 Advanced Cell Diagnostics, Inc. Biomarkers for differentiating melanoma from benign nevus in the skin
SG11201400919RA (en) * 2011-09-23 2014-10-30 Agency Science Tech & Res Patient stratification and determining clinical outcome for cancer patients
CN104684563A (zh) 2012-07-27 2015-06-03 科技研究局(A*Star) 促进伤口愈合的方法
US20160222457A1 (en) * 2012-11-14 2016-08-04 Mayo Foundation For Medical Education And Research Methods and materials for identifying malignant skin lesions
US20170275700A1 (en) * 2014-08-14 2017-09-28 Mayo Foundation For Medical Education And Research Methods and materials for identifying metastatic malignant skin lesions and treating skin cancer
EP3455761B1 (en) 2016-05-10 2021-12-22 Mayo Foundation for Medical Education and Research Methods and materials for staging and treating skin cancer

Also Published As

Publication number Publication date
EP3455761A4 (en) 2019-10-16
US11060151B2 (en) 2021-07-13
AU2017261688B2 (en) 2022-09-29
EA201892562A1 (ru) 2019-05-31
EP3455761A1 (en) 2019-03-20
ES2906987T3 (es) 2022-04-21
AU2017261688A1 (en) 2019-01-03
CA3023506A1 (en) 2017-11-16
US20190169694A1 (en) 2019-06-06
BR112018073014A2 (pt) 2019-02-19
MX388345B (es) 2025-03-19
NZ749045A (en) 2024-11-29
WO2017196944A1 (en) 2017-11-16
EP3455761B1 (en) 2021-12-22
CN109477147A (zh) 2019-03-15

Similar Documents

Publication Publication Date Title
ZA202501583B (en) Compounds and methods for the targeted degradation of androgen receptor
IL280707A (en) Diagnostic and therapeutic methods for the treatment of breast cancer
MX2018010261A (es) Inhibidores de idh1 para el tratamiento de neoplasias malignas hematologicas y tumores solidos.
ZA202004136B (en) Use of chloroquine and clemizole compounds for treatment of inflammatory and cancerous conditions
TW201611847A (en) Compounds and compositions for treating EGFR expressing tumors
CA3055791A1 (en) Treatment methods
MX2022008868A (es) Tratamiento del cancer con tg02.
EA201890957A1 (ru) Комбинированная терапия для лечения злокачественных опухолей
MX2018008426A (es) Combinaciones anti-egfr para tratar tumores.
NZ731467A (en) Anti-tim3 antibodies and methods of use
BR112016024789A2 (pt) métodos de tratamento de câncer de mama em fase inicial com trastuzumabe-mcc-dm1 e pertuzumabe
MX2018008427A (es) Combinaciones anti-cd20 para tratar tumores.
MX2015007185A (es) Uso de eribulina en el tratamiento de cancer de pecho.
PH12021551036A1 (en) Anti-liv1 immune cell cancer therapy
MX2017014735A (es) Metilacion de promotor pd-l1 en cancer.
NZ723884A (en) Methods of treating alzheimer’s disease
MA40458A (fr) Méthodes de traitement du cancer du col de l'utérus
TW201613587A (en) Medical treatments based on anamorelin
AU2015267099A8 (en) Use of eribulin in the treatment of cancer
MX2018013815A (es) Metodos y materiales para estadificar y tratar cancer de piel.
IL276748A (en) Methods for the detection and treatment of prostate cancer
EA201890868A1 (ru) Бактерии с ослабленной вирулентностью для лечения злокачественных солидных опухолей
HK1250626A1 (zh) 借助塞里班土单抗的组合治疗
MX2018006531A (es) Agentes para el tratamiento de enfermedades asociadas con la proliferacion celular no deseada.
IL281439A (en) Combined treatment for blood cancer